Keeping the beat - next-generation heart valves
Tissue Regenix Group Plc (LON:TRX)’s investment story is built on dCELL, a versatile regenerative medical technology and its potential applications across the subsectors: cardiac, wound care and orthopaedics. The cardiac division has a proven technology with the broadest clinical experience, with 10 years of clinical follow-up data recently presented. We maintain our sum-of-the-parts valuation at £338m.
First dCELL human heart valve licenced to JV
In January 2016 Tissue Regenix entered into a joint venture (JV) agreement with a German tissue bank. It has received a non-exclusive licence to its human dCELL heart valves and DermaPure. The JV provides ethical access to human tissue (supply is a limiting factor to commercialisation) and will pursue the regulatory submissions in Germany, potentially leading to a first product launch of dCELL heart valves in 2017. Tissue Regenix intends to replicate this business model to commercialise in other EU jurisdictions in the future.
To read the entire report Please click on the pdf File Below